We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Merck KGaA (PK) | USOTC:MKKGY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.97 | -3.36% | 27.91 | 27.84 | 27.98 | 28.662 | 27.8625 | 28.47 | 107,749 | 17:06:22 |
From Feb 2022 to Feb 2025
By Cecilia Butini
Merck KGaA said Monday that it plans to introduce one new healthcare product every one and a half years as it seeks to double research and development in oncology, neurology and immunology.
The German healthcare and technology company said more than 50% of future launches will result from co-development partnerships with external companies and in-licensing of assets.
The next wave of launches are expected to come from phase-3 trials of head-and-neck cancer medicine xevinapant and evobrutinib, a potential treatment for relapsing multiple sclerosis, the company said.
Merck's expected new launches could be either for new drugs or for new uses of existing drugs, it said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
November 21, 2022 07:48 ET (12:48 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Merck KGaA (PK) Chart |
1 Month Merck KGaA (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
